Bronchial Diseases clinical trials at UC Health

• AcceleRET Lung Study of Pralsetinib for 1L RET Fusion-positive, Metastatic NSCLC

  open to eligible people ages 18 years and up

  This is an international, randomized, open-label, Phase 3 study designed to evaluate whether the potent and selective RET inhibitor, pralsetinib, improves outcome when compared to a platinum chemotherapy-based regimen chosen by the Investigator from a list of standard of care treatments, as measured primarily by progression free survival (PFS), for patients with RET fusion-positive metastatic NSCLC who have not previously received systemic anticancer therapy for metastatic disease. Patients who have centrally confirmed progressive disease on the control arm have the option to crossover to pralsetinib.

  at UC Irvine

Last updated: October 28, 2020